FDA Approved: PREGABALIN — Supplemental Application (ScieGen Pharmaceuticals, Inc)

View source ↗

Summary

FDA approved a supplemental application for pregabalin from ScieGen Pharmaceuticals, Inc., confirming approval of the generic product under ANDA208677.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Peripheral Neuropathy
• Fibromyalgia
• Generalized Anxiety Disorder
• Partial-onset Seizures
• Postherpetic Neuralgia

Drugs mentioned

• Pregabalin (Pregabalin)

Snippet

SUPPL AP for PREGABALIN (PREGABALIN)